Stay updated with breaking news from Drug Pricing Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In a guest column, the executive director of the Epilepsy Foundation writes that the federal 340B Drug Pricing Program, which began with good intentions, is not providing help to all uninsured patients and is allowing hospital corporations to pocket profits.
Abigail Spanberger is leading a bipartisan effort to protect the 340B Drug Pricing Program.
The past two years have featured a flurry of legislative action, agency rulemaking and executive orders targeting the pricing of pharmaceutical and biologic products and related price reporting obligations.
Provider groups asked the court to reverse a nearly 30% cut in 340B reimbursements CMS initiated in 2018, since the agency didn't research hospitals' average drug acquisition costs.
Congresswoman Elise Stefanik has sponsored bipartisan legislation to protect hospitals from losing eligibility for the 340B drug pricing program due to the COVID-19 pandemic. During the COVID-19 …